CORCEPT THERAPEUTICS INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CORCEPT THERAPEUTICS INC (CORT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.10%, a 0.97% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.14%, a 6.98% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.87%, a 96.45% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.97%, a 159.21% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2025-12-31 | 4.10% 10-K · filed 2026-02-24 |
| 2024-12-31 | 4.14% 10-K · filed 2026-02-24 |
| 2023-12-31 | 3.87% 10-K · filed 2026-02-24 |
| 2022-12-31 | 1.97% 10-K · filed 2025-02-26 |
| 2021-12-31 | 0.76% 10-K · filed 2024-02-15 |
| 2020-12-31 | 1.20% 10-K · filed 2023-02-28 |
| 2019-12-31 | 2.34% 10-K · filed 2022-02-15 |
| 2018-12-31 | 2.68% 10-K · filed 2021-02-23 |
| 2017-12-31 | 1.99% 10-K · filed 2020-02-24 |
| 2016-12-31 | 1.31% 10-K · filed 2019-02-26 |
| 2015-12-31 | 1.77% 10-K · filed 2018-02-28 |
| 2014-12-31 | 1.80% 10-K · filed 2017-03-06 |
| 2013-12-31 | 1.76% 10-K · filed 2016-03-10 |
| 2012-12-31 | 1.06% 10-K · filed 2015-03-13 |
| 2011-12-31 | 2.65% 10-K · filed 2014-03-14 |
| 2010-12-31 | 1.83% 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |